case | 26 Mar 2024
Setterwalls advises Alligator Bioscience in connection with rights issue of approximately SEK 150 million
![Responsive image](https://setterwalls.se/wp-content/uploads/2024/01/Setterwalls-Forskning-detalj-1200x500.jpg)
Setterwalls advises Alligator Bioscience AB (“Alligator”), listed on Nasdaq Stockholm, in connection with a rights issue of units of approximately SEK 150 million with an over-allotment issue of up to an additional approximately SEK 100 million.
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s shares are listed on Nasdaq Stockholm, and the company is headquartered in Lund, Sweden.
Contact:
Practice areas: